Association of British Clinical Diabetologists (ABCD) position statement on the use of biosimilar insulin

Published in The British Journal of Diabetes Vol 18, No 4 (2018)


Biosimilar insulins have the potential to offer the NHS a considerable cost saving. The acceptability and use of biosimilar insulin by clinicians and patients may, however, be limited by lack of experience, understanding and concerns about safety and tolerability. This article summarises information on the advantages and disadvantages of using biosimilar insulins and an overview of the published evidence in relation to efficacy, tolerability and safety of current and expected Biosimilar Insulins. The position of the ABCD on the use of Biosimilar Insulin is stated along with the key practical considerations for healthcare staff involved in insulin prescription and administration.

Clinical taxonomy: 
Treatments for diabetes
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Resource taxonomy: 
Position Paper